Skip to main content

What’s new with neuroprotective agents in stroke?

Abstract

Neuroprotective agents demonstrated only modest benefits in several clinical trials reported at the American Heart Association’s 23rd Annual Joint Conference on Stroke and Cerebral Circulation [ Orlando, US; February 1998 ]. No overall benefit emerged from studies of citicoline, clomethiazole or lubeluzole. However, subgroup analyses identified certain patient populations that did derive significant benefit from treatment and that may represent target treatment groups for future trials, delegates were told at the conference.

This is a preview of subscription content, access via your institution.

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bankhead, C. What’s new with neuroprotective agents in stroke?. Inpharma Wkly. 1127, 9–10 (1998). https://doi.org/10.2165/00128413-199811270-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811270-00016

Keywords

  • Placebo Recipient
  • Acute Stroke
  • Acute Ischaemic Stroke
  • Barthel Index
  • Severe Stroke